Funder: National Institutes of Health
Due Dates: September 5, 2025 | January 5, 2026 | April 5, 2026 | September 5, 2026 | January 5, 2027 | April 5, 2027
Funding Amounts: Up to $3,000,000 total over 3 years (no more than $1,500,000 per year); third-party matching funds required.
Summary: Supports SBIR Phase II awardees in pre-clinical research to bridge the funding gap to commercialization, emphasizing third-party investment and partnerships.
Key Information: Clinical trials are not allowed; strong third-party funding is expected and required for most applicants.